The skincare market has undergone a significant structural shift over the past decade. Brands that built their identities on ingredient transparency, clinical credibility, and opposition to luxury skincare pricing are now, in most cases, subsidiaries of the same conglomerates that own the luxury brands they positioned themselves against.

The DECIEM / Ordinary Story

DECIEM was founded in Toronto in 2013 by Brandon Truaxe with an explicit mission to democratise skincare through ingredient transparency and low pricing. The Ordinary became the company's flagship brand and one of the fastest-growing skincare brands in history.

In 2017, Estée Lauder Companies acquired a minority stake in DECIEM. Following the death of Brandon Truaxe in 2019, Estée Lauder increased its stake. In 2021, Estée Lauder acquired a majority stake in DECIEM, valuing the company at approximately $2.2 billion USD. As of 2023, Estée Lauder owns approximately 76% of DECIEM.

"The Ordinary's ingredient transparency is genuine. Its independence is not."

The L'Oréal Dermatological Brands

CeraVe was founded in 2005 and acquired by L'Oréal in 2017 for approximately $1.3 billion USD. La Roche-Posay has been owned by L'Oréal since 1989. Vichy, SkinCeuticals, and Skinceuticals are also L'Oréal properties.

L'Oréal's Active Cosmetics division — which houses these "dermatological" brands — reported revenue of approximately €4.3 billion in 2022. The division's growth has been driven substantially by the dermatologist recommendation channel, which L'Oréal has invested heavily in cultivating.

What This Means for Consumers

Corporate ownership does not automatically compromise product quality or ingredient integrity. The Ordinary's INCI lists remain transparent. CeraVe's formulations remain clinically supported. The ingredients have not changed because the ownership structure changed.

What has changed is the narrative. The "indie" positioning of The Ordinary and the "dermatologist-founded" positioning of CeraVe are marketing constructs that do not reflect the current corporate reality. Consumers who make purchasing decisions based on those narratives deserve to know the full picture.

The INCI list remains the most reliable guide to what is actually in a product. The corporate structure tells you who profits from your purchase. Both are worth knowing.

The Consolidation Timeline

The consolidation of the skincare industry under a small number of conglomerates accelerated dramatically in the 2010s, driven by the "indie beauty" boom. The pattern was consistent: a brand built credibility through ingredient transparency, clinical positioning, or "clean beauty" marketing; grew rapidly on the basis of that credibility; and was then acquired by a conglomerate that recognised the value of the brand's positioning without necessarily sharing its values.

Key acquisitions that reshaped the industry:

2019: Tatcha acquired by Unilever for a reported $500 million. Tatcha had built its identity on Japanese skincare philosophy and "clean" ingredients. Unilever also owns Dove, Vaseline, and Pond's.

2021: The Ordinary's parent company DECIEM acquired by Estée Lauder Companies for approximately $1 billion. The Ordinary had positioned itself as the antithesis of luxury skincare pricing. Estée Lauder also owns La Mer, Bobbi Brown, and MAC.

2019: Drunk Elephant acquired by Shiseido for $845 million. Drunk Elephant had built its identity on the "suspicious 6" — six ingredient categories it avoided. Shiseido also owns NARS, bareMinerals, and Laura Mercier.

2017: CeraVe, La Roche-Posay, and SkinCeuticals are all L'Oréal brands. L'Oréal also owns Lancôme, Kiehl's, Vichy, and Giorgio Armani Beauty.

Why This Matters

The acquisition of "indie" and "clinical" brands by conglomerates has several practical implications for consumers:

Formulation changes: Post-acquisition, brands sometimes reformulate products to reduce costs or align with the parent company's ingredient standards. These changes are rarely announced and may not be reflected in updated marketing materials. The INCI list is the only reliable way to detect formulation changes.

Shared manufacturing: Many brands within the same conglomerate share manufacturing facilities, raw material suppliers, and even formulations. A "luxury" product and a "drugstore" product from the same parent company may contain identical or near-identical formulations at very different price points.

Marketing independence vs. operational integration: Brands typically maintain their marketing independence post-acquisition — the "indie" narrative continues even as operations are integrated into the parent company's supply chain. This creates a gap between brand identity and corporate reality.

Ingredient sourcing: Conglomerates negotiate raw material prices at scale. Post-acquisition, brands may switch to lower-cost raw material sources that meet the same INCI specification but have different quality characteristics. The INCI name does not change; the ingredient quality may.

The "Dermatologist-Founded" and "Clinical" Claims

Several brands use "dermatologist-founded," "dermatologist-tested," or "clinically proven" claims as core brand positioning. These claims require scrutiny:

"Dermatologist-founded" means a dermatologist was involved in founding the company. It does not mean the current formulations are supervised by dermatologists, that the brand's claims are reviewed by independent dermatologists, or that the founding dermatologist has any ongoing role.

"Dermatologist-tested" typically means a small number of dermatologists evaluated the product for tolerability — not efficacy. It is a safety claim, not an efficacy claim.

"Clinically proven" is the most abused claim in skincare marketing. It can mean anything from a rigorous randomised controlled trial to a consumer perception study where participants were asked if they felt their skin looked better. The methodology behind "clinically proven" claims is almost never disclosed.

The Independent Alternatives

A small number of brands have maintained genuine independence from conglomerate ownership. These include:

- Paula's Choice: Founded by Paula Begoun, remains independently owned. Known for evidence-based formulations and ingredient transparency. - Stratia: Small independent brand with a strong formulation science focus. - Chemist Confessions: Founded by two cosmetic chemists, independently owned.

Independent brands are not inherently better than conglomerate-owned brands — formulation quality depends on the specific product, not the ownership structure. But independent brands are less subject to the cost-reduction pressures and marketing-over-science dynamics that can affect post-acquisition brands.

The Bottom Line

The skincare industry's consolidation under a small number of conglomerates is a structural reality that affects formulation decisions, pricing, and marketing claims. Understanding who owns a brand does not tell you whether a specific product is effective — but it provides context for evaluating the brand's claims and motivations.

The INCI list remains the most reliable guide to what is actually in a product. The corporate structure tells you who profits from your purchase. Both are worth knowing.